Efficacy, pharmacokinetics, and safety of icatibant for the treatment of Japanese patients with an acute attack of hereditary angioedema: A phase 3 open-label study

What Was Tested

This clinical trial, phase iii paper looks at Bradykinin and Icatibant.

A phase 3, single-arm, open-label study was performed to evaluate a selective bradykinin B2 receptor antagonist, icatibant, for the treatment of acute attacks in Japanese patients with HAE Type I or II.

Why It Was Studied

Hereditary angioedema (HAE) is a genetic disease characterized by recurrent swelling episodes affecting the skin, gastrointestinal mucosa, and upper respiratory tract.

Who Took Part

By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.

How the Study Was Run

The researchers set it up as a open-label study.

Nothing was hidden in this open-label Bradykinin study: the participants and staff both knew the treatment.

What Was Measured

Hereditary angioedema (HAE) is a genetic disease characterized by recurrent swelling episodes affecting the skin, gastrointestinal mucosa, and upper respiratory tract.

PubMed files the paper under topics including Acute Disease, Angioedemas, Hereditary, Anti-Inflammatory Agents, Non-Steroidal, Bradykinin, Bradykinin B2 Receptor Antagonists, Disease Progression and Japan.

Author keywords: Bradykinin B(2) receptor antagonist, Hereditary angioedema Types I and II, Icatibant and Phase 3 clinical trial.

What This Means in Plain Language

The paper is an open-label study of Bradykinin and Icatibant.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2020 (Allergology international : official journal of the Japanese Society of Allergology), a journal based in England.

More context: the Bradykinin compound page and the Icatibant compound page, all human trials.